Lates News

Telomir Pharmaceuticals (TELO.US): The Q3 2025 financial report recorded revenue of 0 USD, unchanged from the previous value; earnings per share was -0.03 USD, compared to -0.20 USD previously, with an expected value of -0.07 USD.